SCHEMBL22035451

SCHEMBL22035451

Cn1c(=O)n(SS)c(=O)c2ccncc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.40
ADORA2A P29274 3/20 0.40
ADORA1 P30542 2/20 0.40
KDM5A P29375 1/20 0.36
NFATC1 O95644 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
AAK1 Q2M2I8 3/20 0.35
ERCC1 P07992 1/20 0.34
FEN1 P39748 1/20 0.34
ERCC4 Q92889 1/20 0.34
GRM4 Q14833 1/20 0.33
GABRA5 P31644 1/20 0.33
PGR P06401 1/20 0.33
ROCK2 O75116 3/20 0.32
CMA1 P23946 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
PLK1 P53350 1/20 0.32
KDM4C Q9H3R0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13819107 0.80 ADORA3 (0.53) ADORA3ADORA2AADORA1KDM5ANFATC1
SCHEMBL22016877 0.75 ADORA3 (0.41) ADORA3ADORA2AADORA1KDM5ANFATC1
SCHEMBL22016239 0.74 ADORA3 (0.43) ADORA3ADORA2AADORA1KDM5ANFATC1
SCHEMBL1609661 0.70 ADORA3 (0.54) ADORA3ADORA2ANFATC1GSK3BDYRK1A
SCHEMBL22016876 0.70 AAK1 (0.40) ADORA3ADORA2AADORA1KDM5ADYRK1A
SCHEMBL21676745 0.70 DYRK1A (0.43) ADORA3ADORA2AADORA1KDM5ANFATC1
SCHEMBL31425940 0.69 PDE3B (0.44) ADORA3ADORA2AADORA1NFATC1GSK3B
SCHEMBL12251818 0.69 PDE3B (0.44) ADORA3ADORA2AADORA1NFATC1GSK3B
SCHEMBL22016873 0.68 AAK1 (0.39) ADORA3ADORA2AADORA1KDM5ADYRK1A
SCHEMBL9534299 0.67 ADORA3 (0.49) ADORA3ADORA2AADORA1ERCC1FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11179383-B2 Compounds for inhibition of α4β7 integrin GILEAD SCIENCES, INC. (US) 2021-11-23 US disclosed
US-20200163953-A1 Compounds for Inhibition of Alpha 4 Beta 7 Integrin GILEAD SCIENCES, INC. 2020-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200163953-A1 Compounds for Inhibition of Alpha 4 Beta 7 Integrin ITGB7, ITGB4, ITGA4 ADORA3 2207/4885ADORA2A 2997/4885ADORA1 1692/4885
US-11179383-B2 Compounds for inhibition of α4β7 integrin ITGB7, ITGB4, ITGA4 ADORA3 1683/4885ADORA2A 2535/4885ADORA1 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.